{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-015897","form_type":"8-K","ticker":"PTGX","cik":"0001377121","company_name":"Protagonist Therapeutics, Inc","filed_at":"2025-02-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.471904+00:00","generated_at":"2026-05-26T06:53:10.678215+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Protagonist reports Q4 net income $131.7M; cash $559.2M; upcoming Phase 3 readouts in March 2025","bullets":["Net income of $131.7M in Q4 2024 ($2.11 basic EPS) vs $27.3M in Q4 2023; FY 2024 net income $275.2M vs net loss of $79.0M in FY 2023.","License & collaboration revenue of $434.4M for FY 2024, up from $60.0M in FY 2023, including $165M milestone from JNJ.","Cash, equivalents, and marketable securities $559.2M at Dec 31, 2024; plus $165M milestone received Jan 2025; runway through at least end of 2028.","Topline results for rusfertide Phase 3 VERIFY (polycythemia vera) and icotrokinra Phase 2b ANTHEM (ulcerative colitis) expected in March 2025.","Nominated PN-881, an oral IL-17 receptor antagonist; plans to nominate oral obesity candidate in Q2 2025 and oral hepcidin candidate in Q4 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-015897","json":"https://secwatch.observer/filing/0001104659-25-015897.json","markdown":"https://secwatch.observer/filing/0001104659-25-015897.md","text":"https://secwatch.observer/filing/0001104659-25-015897.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1377121/000110465925015897/0001104659-25-015897-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1377121/000110465925015897/tm257151d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T06:53:10.678215+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}